Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
古根海姆将再生元制药公司的目标价格从1,040美元上调至1,180美元,维持买入评级。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册